AMO's IntraLase, Carl Zeiss settle patent row:
This article was originally published in Clinica
Executive Summary
Ophthalmic laser rivals Advanced Medical Optics and Carl Zeiss Meditec have signed a non-exclusive US licence related to patented laser technology for eye surgery. AMO's IntraLase subsidiary has granted Carl Zeiss use of its technology, which the Jena, Germany-based firm will use to provide femtosecond technology for corneal surgery. This agreement settles a dispute from last year where IntraLase filed suit against Carl Zeiss in November 2006 over use of confidential information relating to its ultra-fast laser technology (see Clinica No 1232, p 17) - it was subsequently bought by AMO for $808m in April 2007. Terms of the new agreement were not disclosed.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.